S100A9 and neoplasm: To demonstrate the therapeutic potential of S100A9 inhibitor tasquinimod in combination with venetoclax as a novel therapeutic approach for unfit/frail AML patients, we tested the combination on KG-1a and MOLM-13 cell lines, and 5 primary patient samples with variable tumor loads (Supplemental Table 2).